Skip to main content

Drug repurposing in pancreatic ductal adenocarcinoma

Searching for OpenAIRE data...

Publications

Nischarin agonist rilmenidine inhibits pancreatic ductal adenocarcinoma cell migration and invasion

Author(s): Marijana Pavlovic, Marija Ostojic, Kristina Zivic, Aleksandar Pavic, Tatjana Srdic-Rajic, Jelena Grahovac
Published in: Cancer Research, Volume 82 12_Supplement, 2022, Page(s) 3463-3463
Publisher: The American Association for Cancer Research
DOI: 10.1158/1538-7445.am2022-3463

Nischarin is expressed in pancreatic ductal adenocarcinoma and is a potential target for drug repurposing

Author(s): Jelena Grahovac, Marijana Pavlovic, Marija Ostojic, Kristina Zivic, Daniel Galun and Tatjana Srdic-Rajic
Published in: Cancer Research, Volume 81 22_Supplement, 2021
Publisher: American Association for Cancer Research
DOI: 10.1158/1538-7445.panca21-po-040

Nischarin expression may have differing roles in male and female melanoma patients

Author(s): Marija Ostojić, Marko Jevrić, Olivera Mitrović-Ajtić, Miljana Tanić, Milena Čavić, Tatjana Srdić-Rajić Jelena Grahovac
Published in: 2022
Publisher: Research Square
DOI: 10.21203/rs.3.rs-1576440/v2